Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 10/20 | 1.00 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.61 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.61 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.61 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | SHBG | P04278 | 2/20 | 0.59 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.59 |
| ▸ | HSD17B3 | P37058 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.59 |
| ▸ | G6PD | P11413 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL334388 | 1.00 | CYP19A1 (1.00) | CYP19A1AKR1B10AKR1B1OR51E2GPBAR1 | |
| SCHEMBL334387 | 1.00 | CYP19A1 (1.00) | CYP19A1AKR1B10AKR1B1OR51E2GPBAR1 | |
| SCHEMBL13301261 | 1.00 | CYP19A1 (1.00) | CYP19A1AKR1B10AKR1B1OR51E2GPBAR1 | |
| SCHEMBL4584277 | 1.00 | CYP19A1 (1.00) | CYP19A1AKR1B10AKR1B1OR51E2GPBAR1 | |
| Sulfuric Acid SCHEMBL9022915 | 0.94 | CYP19A1 (0.88) | CYP19A1AKR1B10AKR1B1OR51E2GPBAR1 | |
| Sulfuric Acid SCHEMBL7467213 | 0.94 | CYP19A1 (0.88) | CYP19A1AKR1B10AKR1B1OR51E2GPBAR1 | |
| SCHEMBL20166975 | 0.82 | CYP19A1 (0.70) | CYP19A1AKR1B10AKR1B1OR51E2GPBAR1 | |
| SCHEMBL1460891 | 0.82 | CYP19A1 (0.70) | CYP19A1AKR1B10AKR1B1OR51E2GPBAR1 | |
| SCHEMBL16659742 | 0.82 | CYP19A1 (0.69) | CYP19A1AKR1B10AKR1B1OR51E2GPBAR1 | |
| SCHEMBL11648596 | 0.80 | CYP19A1 (0.67) | CYP19A1AKR1B10AKR1B1OR51E2GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119591653-A | Synthesis method of 5 alpha-androstane-2-alkene-17-ketone | 上海药坦药物研究开发有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-114728060-A | Methods of treating lupus nephritis using interleukin-17 (IL-17) antagonists | 诺华股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-113637043-A | Preparation method of 5 alpha-androst-2-ene-17 ketone | 重庆康乐制药有限公司 | 2021-11-12 | — | — | CN | disclosed |
| US-20130164780-A1 | Drug Identification Method | BIOVIE INC. | 2013-06-27 | — | — | US | disclosed |
| US-20130164780-A1 | Drug Identification Method | BIOVIE INC. | 2013-06-27 | — | — | US | disclosed |
| US-8354396-B2 | Identifying compounds that can treat autoimmune conditions; ulcerative colitis, inflammatory bowel disease, Crohn's disease, psoriasis, actinic keratosis, arthritis, multiple sclerosis, optic neuritis | Harbor Therapeutics, Inc. (US) | 2013-01-15 | — | — | US | disclosed |
| US-8354396-B2 | Identifying compounds that can treat autoimmune conditions; ulcerative colitis, inflammatory bowel disease, Crohn's disease, psoriasis, actinic keratosis, arthritis, multiple sclerosis, optic neuritis | Harbor Therapeutics, Inc. (US) | 2013-01-15 | — | — | US | disclosed |
| EP-2486924-A2 | Drugs and uses | Harbor BioSciences, Inc. (US) | 2012-08-15 | — | — | EP | disclosed |
| US-8217025-B2 | Utilizing such as 4-fluoro-17-ethynylandrost-5-ene-3-,7-,17-triol; pulmonary conditions, hyperglycemia, type 2 diabetes, insulin resistance | Harbor Therapeutics, Inc. (US) | 2012-07-10 | — | — | US | disclosed |
| US-8217025-B2 | Utilizing such as 4-fluoro-17-ethynylandrost-5-ene-3-,7-,17-triol; pulmonary conditions, hyperglycemia, type 2 diabetes, insulin resistance | Harbor Therapeutics, Inc. (US) | 2012-07-10 | — | — | US | disclosed |
| EP-2012773-B1 | DRUGS AND USES | HARBOR BIOSCIENCES INC (US) | 2012-06-20 | — | — | EP | disclosed |
| US-20080221074-A1 | Drug Screen and Treatment Method | BIOVIE INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221074-A1 | Drug Screen and Treatment Method | BIOVIE INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080153792-A1 | Drug Identification and Treatment Method | BIOVIE INC. | 2008-06-26 | — | — | US | disclosed |
| US-20080153792-A1 | Drug Identification and Treatment Method | BIOVIE INC. | 2008-06-26 | — | — | US | disclosed |
| US-20080153797-A1 | Drug Identification and Treatment Method | BIOVIE INC. | 2008-06-26 | — | — | US | disclosed |
| US-20080153797-A1 | Drug Identification and Treatment Method | BIOVIE INC. | 2008-06-26 | — | — | US | disclosed |
| US-20080146532-A1 | Utilizing such as 4-fluoro-17-ethynylandrost-5-ene-3-,7-,17-triol; pulmonary conditions, hyperglycemia, type 2 diabetes, insulin resistance | BIOVIE INC. | 2008-06-19 | — | — | US | disclosed |
| US-20080146532-A1 | Utilizing such as 4-fluoro-17-ethynylandrost-5-ene-3-,7-,17-triol; pulmonary conditions, hyperglycemia, type 2 diabetes, insulin resistance | BIOVIE INC. | 2008-06-19 | — | — | US | disclosed |
| WO-2008039566-A2 | DRUGS AND USES | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153792-A1 | Drug Identification and Treatment Method | PTGER4, PTGER1, IL17A | CYP19A1 271/4885AKR1B10 362/4885AKR1B1 137/4885 |
| US-20080146532-A1 | Utilizing such as 4-fluoro-17-ethynylandrost-5-ene-3-,7-,17-triol; pulmonary conditions, hyperglycemia, type 2 diabetes, insulin resistance | HSD17B1, HSD17B11, HSD3B2 | CYP19A1 105/4885AKR1B10 350/4885AKR1B1 91/4885 |
| US-20080221074-A1 | Drug Screen and Treatment Method | HSD3B2, HSD17B2, HSD3B1 | CYP19A1 42/4885AKR1B10 205/4885AKR1B1 74/4885 |
| US-20080153797-A1 | Drug Identification and Treatment Method | PTGER4, PTGER1, IL17A | CYP19A1 245/4885AKR1B10 351/4885AKR1B1 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.